InterMune, Inc. has signed its second drug discovery contract with Evotec AG under which Evotec will support InterMune’s research efforts with its medicinal chemistry expertise. Evotec will use its technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further characterize active compounds and optimize their potency and selectivity to generate lead molecules for advancement into clinical trials.     This contract expands the existing collaboratio...